The difficulty of finding the best way to find missing primary cancers

November 24, 2020

By Lois Wingerson

Yesterday Rosetta Genomics, an aptly named firm based in Israel that specializes in molecular profiling of tissues, finally won back in arbitrations the right to distribute its own cancer diagnostic tests in the United States. This ends an 18-month legal wrangle with its former US distributor, Prometheus Laboratories, over funding disputes. You'd think this would be an auspicious time to regain the rights to the test that it calls miRview mets, which identifies tissues of origin for metastatic cancers with an unknown primary (CUP).

FDA approves new treatment option for late-stage breast cancer

November 15, 2020

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate) to treat patients with metastatic breast cancer who have received at least two prior chemotherapy regimens for late-stage disease.

Antibody Slows Bone Events in Breast Cancer

November 9, 2020

By Charles Bankhead, Staff Writer, MedPage Today

Bone-related adverse events such as fractures occurred significantly less often in patients with advanced breast cancer treated with the monoclonal antibody denosumab (Prolia) compared with zoledronic acid (Zometa), according to data from a large, randomized trial.

Novel Drug Study Led by Arizona Cancer Center Physician Scientist Shows Benefits for Cancer Patients with Bone Metastases

November 9, 2020

By Arizona Cancer Center

(HealthNewsDigest.com) - Monthly injections of a new drug in breast cancer patients whose disease has spread to the bone can delay and reduce pain and prevent complications with less toxicity than other treatments available, according to results of a worldwide study reported by Alison T. Stopeck, MD, director of the Arizona Cancer Center’s clinical breast cancer program and lead author of a paper appearing in the Nov. 8 issue of the Journal of Clinical Oncology.